Page 26 - 84_04

Obesity: a risk for Alzheimer's disease? II. Connecting therapies
Disease.. Cell Stem Cell 2015;17(4):397-411.
31. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR,
Tavares R, et al. Impaired insulin and insulin-like
growth factor expression and signaling mechanisms in
Alzheimer's disease--is this type 3 diabetes? J
Alzheimers Dis 2005;7(1):63-80.
32. Moloney AM, Griffin RJ, Timmons S, O'Connor R,
Ravid R, O'Neill C. Defects in IGF-1 receptor, insulin
receptor and IRS-1/2 in Alzheimer's disease indicate
possible resistance to IGF-1 and insulin signalling.
Neurobiol Aging 2010;31(2): 224-43.
33. De la Monte SM. Insulin resistance and Alzheimer's
disease. BMB Rep 2009;42(8):475-81
34. Kroner Z. The relationship between Alzheimer's
disease and diabetes: Type 3 diabetes?. Altern Med
Rev 2009;14(4):373-9.
35. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR,
de la Monte SM. Insulin and insulin-like growth factor
expression and function deteriorate with progression
of AD: link to brain reductions in acetylcholine. J
Alzheimers Dis 2005;8(3):247-68.
36. Arab L, Sadeghi R, Walker D, Lue L, Sabbagh M.
Consequences of Aberrant Insulin Regulation in the
Brain: Can Treating Diabetes be Effective for
Alzheimer's Disease. Curr Neuropharmacol
2011;9(4):693-705.
37. Correia SC, Santos RX, Perry G, Zhu X, Moreira PI,
Smith MA. Insulin-resistant brain state: the culprit in
sporadic Alzheimer's disease? Ageing Res Rev
2011;10(2):264-73.
38. Craft S. Insulin resistance syndrome and Alzheimer's
disease: age- and obesity-related effects on memory,
amyloid, and inflammation. Neurobiol Aging,
2005;26(Suppl 1):65-9.
39. Kuljis RO, Salkovic-Petrisic M. Dementia, diabetes,
Alzheimer's disease, and insulin resistance in the
brain: progress, dilemmas, new opportunities, and a
hypothesis to tackle intersecting epidemics. J
Alzheimers Dis 2011; 25(1):29-41.
40. Phillips C, Baktir MA, Das D, Lin B, Salehi A. The
link between physical activity and cognitive
dysfunction in Alzheimer Disease. Phys Ther
2015;95(7):1046-60.
41. Flicker L. Modifiable lifestyle risk factors for
Alzheimer's disease. J Alzheimers Dis
2010;20(3):803-11.
42 Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino
G, Imbimbo BP, Pilotto A. Diet and Alzheimer's
disease risk factors or prevention: the current
evidence. Expert Rev Neurother 2011;11(5):677-708.
43. Shah R. The role of nutrition and diet in Alzheimer
disease: a systematic review. J Am Med Dir Assoc
2013;14(6):398-402.
44. Morris MC, Evans DA, Tangney CC, Bienias JL,
Wilson RS. Associations of vegetable and fruit
consumption with age-related cognitive change.
@Real Academia Nacional de Farmacia. Spain
Neurology 2006;67(8):1370-6.
45. Velloso LA, Schwartz MW. Altered hypothalamic
function in diet-induced obesity. Int J Obes (Lond)
2011;35(12):1455-65.
46. Kumar A, Nisha CM, Silakari C, Sharma I, Anusha K,
Gupta N, Nair P, Tripathi T, Kumar A.. Current and
novel therapeutic molecules and targets in Alzheimer's
disease. J Formos Med Assoc 2015.
47. Mehta M, Adem A, Sabbagh M. New
acetylcholinesterase inhibitors for Alzheimer's
disease. Int J Alzheimers Dis 2012;2012:728983.
48. Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig
NH, Rogers JT, Huang X.N-methyl D-aspartate
(NMDA) receptor antagonists and memantine
treatment for AD, vascular dementia and Parkinson's
disease. Curr Alzheimer Res 2012;9(6):746-58.
49. Rodgers RJ, Tschop MH, Wilding JP. Anti-obesity
drugs: past, present and future. Dis Model Mech
2012;5(5):621-6.
50. Kral JG, Naslund E. Surgical treatment of obesity. Nat
Clin Pract Endocrinol Metab 2007;3(8):574-83.
51. Carmona P, Rodríguez-Casado A, Alvarez I, Toledano
A. FTIR Microspectroscopic Analysis of the effects of
some drugs on oxidative stress and brain protein
structure. Biopolymers 2008;89:548-554.
52. Kennett GA, Clifton PG. New approaches to the
pharmacological treatment of obesity: can they break
through the efficacy barrier? Pharmacol Biochem
Behav 2010;97(1):63-83.
53. Astrup A, Carraro R, Finer N, Harper A, Kunesova M,
Lean ME, et al . Safety, tolerability and sustained
weight loss over 2 years with the once-daily human
GLP-1 analog, liraglutide. Int J Obes (Lond)
2012;36(6):843-54.
54. Hofman A, Brusselle GG, Darwish Murad S, van
Duijn CM, Franco OH, Goedegebure A, et al. The
Rotterdam Study: 2016 objectives and design update.
Eur J Epidemiol 2015;30(8):661-708.
55. Adan RA, Vanderschuren LJ, La Fleur SE. Anti-
obesity drugs and neural circuits of feeding. Trends
Pharmacol Sci 2008;29(4):208-17.
56. Sargent BJ, Moore NA. New central targets for the
treatment of obesity. Br J Clin Pharmacol
2009;68(6):852-60.
57. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ.
Enhanced weight loss following coadministration of
pramlintide with sibutramine or phentermine in a
multicenter trial. Obesity (Silver Spring)
2010;18(9):1739-46
58. Ettcheto M, Sánchez-López E, Gómez-Mínguez Y,
Cabrera H, Busquets O, Beas-Zarate C, et al. Peripheral
and Central Effects of Memantine in a Mixed Preclinical
Mice Model of Obesity and Familial Alzheimer's
Disease. Mol Neurobiol. 2018; 55:7327-7339
59. Verspohl EJ. Novel pharmacological approaches to the
treatment of T2D. Pharmacol Rev 2012;64(2):188-
237.
60. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The
355